Cargando…
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609722/ https://www.ncbi.nlm.nih.gov/pubmed/31273200 http://dx.doi.org/10.1038/s41398-019-0507-5 |
_version_ | 1783432366909292544 |
---|---|
author | Bhattacharyya, Sudeepa Ahmed, Ahmed T. Arnold, Matthias Liu, Duan Luo, Chunqiao Zhu, Hongjie Mahmoudiandehkordi, Siamak Neavin, Drew Louie, Gregory Dunlop, Boadie W. Frye, Mark A. Wang, Liewei Weinshilboum, Richard M. Krishnan, Ranga R. Rush, A. John Kaddurah-Daouk, Rima |
author_facet | Bhattacharyya, Sudeepa Ahmed, Ahmed T. Arnold, Matthias Liu, Duan Luo, Chunqiao Zhu, Hongjie Mahmoudiandehkordi, Siamak Neavin, Drew Louie, Gregory Dunlop, Boadie W. Frye, Mark A. Wang, Liewei Weinshilboum, Richard M. Krishnan, Ranga R. Rush, A. John Kaddurah-Daouk, Rima |
author_sort | Bhattacharyya, Sudeepa |
collection | PubMed |
description | Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD(17)) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that are known to be influenced by human gut microbial cometabolism. 5HT, 5-hydroxyindoleacetate (5HIAA), and the ratio of 5HIAA/5HT showed significant correlations to temporal changes in HRSD(17) scores. In the tyrosine pathway, changes were observed in the end products of the catecholamines, 3-methoxy-4-hydroxyphenylethyleneglycol and vinylmandelic acid. Furthermore, two phenolic acids, 4-hydroxyphenylacetic acid and 4-hydroxybenzoic acid, produced through noncanconical pathways, were increased with drug exposure. In the purine pathway, significant reductions in hypoxanthine and xanthine levels were observed. Examination of metabolite interactions through differential partial correlation networks revealed changes in guanosine–homogentisic acid and methionine–tyrosine interactions associated with HRSD(17). Genetic association studies using the ratios of these interacting pairs of metabolites highlighted two genetic loci harboring genes previously linked to depression, neurotransmission, or neurodegeneration. Overall, exposure to escitalopram/citalopram results in shifts in metabolism through noncanonical pathways, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms. |
format | Online Article Text |
id | pubmed-6609722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66097222019-07-08 Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients Bhattacharyya, Sudeepa Ahmed, Ahmed T. Arnold, Matthias Liu, Duan Luo, Chunqiao Zhu, Hongjie Mahmoudiandehkordi, Siamak Neavin, Drew Louie, Gregory Dunlop, Boadie W. Frye, Mark A. Wang, Liewei Weinshilboum, Richard M. Krishnan, Ranga R. Rush, A. John Kaddurah-Daouk, Rima Transl Psychiatry Article Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD(17)) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that are known to be influenced by human gut microbial cometabolism. 5HT, 5-hydroxyindoleacetate (5HIAA), and the ratio of 5HIAA/5HT showed significant correlations to temporal changes in HRSD(17) scores. In the tyrosine pathway, changes were observed in the end products of the catecholamines, 3-methoxy-4-hydroxyphenylethyleneglycol and vinylmandelic acid. Furthermore, two phenolic acids, 4-hydroxyphenylacetic acid and 4-hydroxybenzoic acid, produced through noncanconical pathways, were increased with drug exposure. In the purine pathway, significant reductions in hypoxanthine and xanthine levels were observed. Examination of metabolite interactions through differential partial correlation networks revealed changes in guanosine–homogentisic acid and methionine–tyrosine interactions associated with HRSD(17). Genetic association studies using the ratios of these interacting pairs of metabolites highlighted two genetic loci harboring genes previously linked to depression, neurotransmission, or neurodegeneration. Overall, exposure to escitalopram/citalopram results in shifts in metabolism through noncanonical pathways, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms. Nature Publishing Group UK 2019-07-04 /pmc/articles/PMC6609722/ /pubmed/31273200 http://dx.doi.org/10.1038/s41398-019-0507-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Bhattacharyya, Sudeepa Ahmed, Ahmed T. Arnold, Matthias Liu, Duan Luo, Chunqiao Zhu, Hongjie Mahmoudiandehkordi, Siamak Neavin, Drew Louie, Gregory Dunlop, Boadie W. Frye, Mark A. Wang, Liewei Weinshilboum, Richard M. Krishnan, Ranga R. Rush, A. John Kaddurah-Daouk, Rima Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
title | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
title_full | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
title_fullStr | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
title_full_unstemmed | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
title_short | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
title_sort | metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609722/ https://www.ncbi.nlm.nih.gov/pubmed/31273200 http://dx.doi.org/10.1038/s41398-019-0507-5 |
work_keys_str_mv | AT bhattacharyyasudeepa metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT ahmedahmedt metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT arnoldmatthias metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT liuduan metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT luochunqiao metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT zhuhongjie metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT mahmoudiandehkordisiamak metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT neavindrew metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT louiegregory metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT dunlopboadiew metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT fryemarka metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT wangliewei metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT weinshilboumrichardm metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT krishnanrangar metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT rushajohn metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients AT kaddurahdaoukrima metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients |